What is the recommended treatment and management for myelofibrosis?

Myelofibrosis Treatment and Management

For myelofibrosis, treatment should be risk-stratified: allogeneic stem cell transplantation for high/intermediate-2 risk transplant-eligible patients, ruxolitinib as first-line therapy for symptomatic intermediate-2/high-risk disease with splenomegaly, and observation for low-risk asymptomatic patients.

Risk Stratification Framework

Risk stratification drives all treatment decisions in myelofibrosis. Use MIPSS70+ version 2.0 or GIPSS for prognostication 1, 2. These incorporate:

• Clinical factors (age, constitutional symptoms, hemoglobin, white blood cell count, platelet count, blast percentage)
• Cytogenetics (very high-risk: -7, inv(3), i(17q), +21, +19, 12p-, 11q-)
• Molecular mutations (SRSF2, ASXL1, U2AF1-Q157 predict inferior survival; type 1/like CALR mutations predict superior survival)

The MIPSS70+ v2.0 stratifies patients into very low, low, intermediate, high, and very high-risk categories with 10-year survival ranging from 92% (very low) to 0% (very high) 2.

Treatment Algorithm by Risk Category

High and Intermediate-2 Risk Disease

Allogeneic hematopoietic stem cell transplantation (alloSCT) is the only curative option and should be pursued in all transplant-eligible patients 1, 3. Key transplant considerations:

• HLA-matched sibling donors remain the preferred donor source 3
• Both reduced-intensity conditioning and myeloablative conditioning are valid options 3
• Pre-transplant spleen management: Patients with splenomegaly >5 cm below left costal margin should receive JAK inhibitor therapy before transplant 3
• Post-transplant monitoring: Regular driver mutation monitoring is recommended to detect early relapse and treat with donor lymphocyte infusion 3

For transplant-ineligible patients with intermediate-2 or high-risk disease:

• Ruxolitinib is first-line therapy for MF-associated splenomegaly 1
• Fedratinib or pacritinib for ruxolitinib-refractory disease 2
• Momelotinib is particularly effective for patients with moderate to severe anemia 4, 2

Intermediate-1 Risk Disease

AlloSCT is recommended for transplant-eligible patients with any of the following high-risk features 1:

• Refractory, transfusion-dependent anemia
• Peripheral blood blasts >2%
• Adverse cytogenetics
• High-risk mutations (ASXL1, SRSF2, U2AF1-Q157)

For patients without these features:

• Ruxolitinib is indicated only for highly symptomatic splenomegaly 1
• Otherwise, observation with close monitoring every 3-6 months

Low and Very Low-Risk Disease

Observation alone is appropriate 2. The estimated 10-year survival is 56-92%, making aggressive intervention unnecessary unless symptoms develop.

Monitor for:

• Progressive splenomegaly
• Development of constitutional symptoms (pruritus, night sweats, fatigue)
• Progressive cytopenias
• Increasing blast count

JAK Inhibitor Selection and Sequencing

First-Line JAK Inhibitor Therapy

Ruxolitinib remains the standard first-line JAK inhibitor for symptomatic disease 1, 2. However, baseline characteristics should guide initial selection:

• Momelotinib for patients with moderate-to-severe anemia or transfusion dependence 4, 2
• Pacritinib for patients with platelet count <50 × 10⁹/L 2
• Ruxolitinib for all others with symptomatic splenomegaly or constitutional symptoms

After Ruxolitinib Failure

Ruxolitinib failure is defined by:

• Loss of spleen response (≥25% increase from nadir)
• Persistent splenomegaly despite adequate dosing
• Development of new cytopenias
• Progressive symptoms despite therapy

Second-line options include 2, 5:

• Fedratinib (particularly if spleen response was initially achieved with ruxolitinib)
• Pacritinib (if thrombocytopenia is limiting)
• Momelotinib (if anemia is the primary concern)

Management of Specific Complications

Anemia Management

For symptomatic anemia in MF:

• Momelotinib is the preferred JAK inhibitor due to its erythropoietic benefits 4, 2
• Erythropoiesis-stimulating agents may be considered in select patients
• Transfusion support as needed
• Danazol or immunomodulatory agents (lenalidomide, thalidomide) for non-JAK inhibitor candidates

Splenomegaly Refractory to Medical Therapy

Splenectomy is reserved for drug-refractory splenomegaly 2. This carries significant perioperative risk and should only be performed at experienced centers.

Splenic radiation therapy is an alternative for patients who are poor surgical candidates, though responses are typically temporary 2.

Extramedullary Hematopoiesis

Involved field radiotherapy for non-hepatosplenic extramedullary hematopoiesis and extremity bone pain 2.

Critical Pitfalls to Avoid

1. Do not delay alloSCT evaluation in high-risk patients: Transplant should be discussed early, as disease progression may render patients ineligible
2. Do not use cytoreductive therapy in low-risk asymptomatic patients: This provides no survival benefit and adds toxicity
3. Do not continue ineffective JAK inhibitor therapy: Recognize failure early and switch agents rather than persisting with suboptimal treatment
4. Do not overlook pre-transplant spleen management: Uncontrolled splenomegaly increases transplant-related complications 3
5. Bone marrow biopsy before initiating cytoreductive therapy: Rule out disease progression to ensure appropriate treatment selection 6

Monitoring and Follow-Up

For patients on observation or medical therapy:

• Clinical assessment every 3-6 months or more frequently if symptomatic 6
• Complete blood counts at each visit
• Bone marrow biopsy if clinical deterioration suggests progression
• Mutation monitoring in post-transplant patients to detect molecular relapse 3

The landscape of MF therapy is rapidly evolving with multiple novel agents in clinical trials, including combination therapies with JAK inhibitors and agents targeting alternative pathways 7, 8. However, the current evidence-based approach remains risk-stratified with alloSCT for curative intent in appropriate candidates and JAK inhibitors for symptom palliation in others.